Insights From The Responsible Business Conduct, Innovation and AI Symposium ‘22

An insight from Dr Seán Costello – Director, Innopharma Technology

As the old adage goes “With great power comes great responsibility”. What follows below is an interesting account by our very own Dr Seán Costello after recently attending an event to consider ethical and responsible business practices in the use of Artificial Intelligence. 

I had a really interesting start to the week where I attended as a panel speaker a symposium hosted by Intel and Article One in association with the School of Law at Trinity College Dublin. The Symposium was a day for debating and discussing the areas of responsible business conduct and innovation with respect to the ethical use of Artificial Intelligence. 

In an age where we are experiencing a recession on Human Rights, privacy and increased authoritarian efforts to exert control, the context and gravity of the issues discussed at the event with respect to human rights, privacy, and personal and societal freedoms are important to consider. These were established early by the presence of keynote speaker Eamon Gilmore, the EU Special Representative for Human Rights where he expressed the commitment of the EU to do its part to ensure the responsible use of such technology. 


The intention of the symposium was to delve into issues around responsible development and deployment of Artificial Intelligence (AI).  The emergence of new international standards and regulations on responsible business conduct was discussed in a way that respects all stakeholder expectations while at the same time ensuring that the Human Rights framework is reflected in the efforts to define best practices, standards and regulations in the ethical deployment of AI. 

These were weighty topics, but increasingly relevant as AI increasingly pervades all aspects of our lives. I was part of a panel alongside Lama Nachman from Intel, Matt Moran BioPharmaChem Ireland and chaired by Erik O’Donovan, Head of Digital Economy Policy at IBEC. In this we shared our experience of the practical issues surrounding the responsible deployment of AI in manufacturing.  

During the days debate I couldn’t help but draw parallels between the challenges facing policy makers and other stakeholder in setting standards and regulations for the responsible and ethical use of AI today. and the raison d'etre for the emergence of Regulators such as the FDA and EMA in the manufacture of medicines. The birth of the FDA and more recently the EMA was driven by historical ethical challenges such as mislabelling, misbranding, adulteration and contamination (both deliberate and unintended) of medicinal products by corporations and individuals. It required measures for the protection of the public and became the drivers for the culture of responsible governance that we have today in pharmaceutical, food and medical device manufacturing. 

Surely lessons can be learned from this analogous perspective that are equally attributable today to the responsible use of AI.   


Listening to this discussion taking place on the campus which hosts the oldest school of medicine in Ireland, I could not help but link much of what was being discussed to the maxim ‘primum non nocere’ (first, do no harm) attributed to the ancient Greek physician Hippocrates on whose oath is the principal precepts of bioethics that all students in healthcare abide by even today.

Perhaps such a similar oath or code of conduct is a starting point for us all in the ethical use of AI.  

Well done to Article One, Intel, School of Law at TCD for a superb event and to Paula Williams, Global Programme Owner for Human Rights at Intel for the invitation to participate.   

Sean Costello

Sean Costello leads the Technology Division, applying Industry 5.0 solutions to pharmaceutical, food and fine chemical industries. Prior to Innopharma, Sean was a founder of a Medical Device company and University spin-out SlidePath, which developed cloud-enabled AI-driven diagnostic decision support and automated workflow solutions for clinical histopathology, pharma drug discovery and drug safety. Sean holds a PhD in Pathology Imaging and Medical Informatics and a BSc in Biotechnology.

Darren McHugh

Darren McHugh is a Senior Product Manager at Innopharma Technology, with over 18 years of experience in the field of Manufacturing. He holds separate degrees in: Mechanical Engineering, Manufacturing Engineering, Pharmaceutical and Medical Device Manufacturing, and a Master’s in Product Management. He has worked with several companies in the manufacturing industry to help them implement smart manufacturing solutions into their processes. Darren is an expert in Industry 4.0 and 5.0 solutions, where he has used IIoT, image analysis and machine learning (ML) technologies to help companies capture the full potential of their digital transformation efforts and deliver a satisfactory return on investment.

Liam Ryan

Liam Ryan is a Sales & Marketing Manager at Innopharma Technology with over 12 years in Technology and Food & Beverage sectors. He has specialized in international business spending years working in China, US, Middle East & Europe with strong experience in the commercialization of new technologies in the marketplace.

SmartX Process Automation Platform

SmartXTM gives department teams better understanding of how critical process input parameters such as machine settings, operator training levels, or raw material options will affect product quality and outcomes.


Pharma Industry Awards 2021 Proud Sponsor